Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 20/20 | 0.80 |
| ▸ | TRPV4 | Q9HBA0 | 7/20 | 0.74 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10275162 | 0.94 | TRPA1 (0.80) | TRPA1TRPV4TRPV3 | |
| SCHEMBL10275718 | 0.92 | TRPA1 (0.76) | TRPA1TRPV4TRPV3 | |
| SCHEMBL10275142 | 0.89 | TRPA1 (0.84) | TRPA1TRPV4 | |
| SCHEMBL10275886 | 0.89 | TRPA1 (1.00) | TRPA1TRPV4 | |
| SCHEMBL10280441 | 0.88 | TRPA1 (0.73) | TRPA1TRPV4TRPV3 | |
| SCHEMBL10275318 | 0.87 | TRPA1 (0.81) | TRPA1TRPV4 | |
| SCHEMBL10280442 | 0.87 | TRPA1 (0.78) | TRPA1TRPV4TRPV3 | |
| SCHEMBL13834363 | 0.87 | TRPA1 (0.71) | TRPA1TRPV4TRPV3 | |
| SCHEMBL10275308 | 0.87 | TRPA1 (1.00) | TRPA1TRPV4 | |
| SCHEMBL10275057 | 0.87 | TRPA1 (0.80) | TRPA1TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411395-B1 | FUROPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2013-05-29 | — | — | EP | claimed |
| US-20120178766-A1 | FUROPYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-07-12 | — | — | US | claimed |
| EP-2411395-B1 | FUROPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-20120178766-A1 | FUROPYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-07-12 | — | — | US | disclosed |
| US-20120178766-A1 | FUROPYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-07-12 | — | — | US | disclosed |
| WO-2010109329-A1 | FUROPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178766-A1 | FUROPYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS | TRPA1, TRPV1, TRPC3 | TRPA1 1/4885TRPV4 11/4885TRPV3 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.